PMID- 8023771
OWN - NLM
STAT- MEDLINE
DCOM- 19940803
LR  - 20121115
IS  - 0018-1994 (Print)
IS  - 0018-1994 (Linking)
VI  - 40
IP  - 5
DP  - 1994 May
TI  - [Re-examination of the criteria for clinical evaluation on bacterial 
      prostatitis--analysis of the data of the clinical study of temafloxacin].
PG  - 455-66
AB  - The clinical efficacy of temafloxacin (TMFX) was evaluated in the patients with 
      acute prostatitis (AP: 31 cases) and chronic prostatitis (CP: 75 cases), and the 
      criteria for clinical evaluation on bacterial prostatitis by the Japanese UTI 
      Committee were re-examined. The clinical efficacy of TMFX on prostatitis was 
      examined. The number of the evaluable cases by doctors in charge were 30 and 68 
      for AP and CP, respectively. The efficacy rates were as high as 96.7% for AP and 
      80.9% for CP. In the patients whose efficacy could be evaluated by the Committee, 
      the efficacy rates were as high as 100% (15/15) for acute bacterial prostatitis 
      (ABP) and 66.7% (18/27) for chronic bacterial prostatitis (CBP). The 
      bacteriological eradication rates were 100% (15/15) for ABP and 81.5% (22/27) for 
      CBP. Adverse drug reactions were observed in 8 of 100 cases (total evaluable 
      cases) but they clinically did not consist any problems. Abnormal laboratory test 
      findings were observed in 9 of 71 cases (total evaluable cases), whose changes 
      were all slight and did not clinically cause any problem. Therefore, TMFX was 
      concluded to be highly useful in the treatment of ABP and CBP. The criteria for 
      clinical evaluation on bacterial prostatitis were re-examined. Concerning the 
      treatment period, comparison of the evaluation at Day 7 with that at Day 14 in 
      ABP revealed that the efficacy was evaluable at Day 7. In the same way, 
      comparison of the evaluation at Day 14 with that at Day 28 in CBP revealed that 
      the efficacy was evaluable at Day 14. Concerning the pathogens, in ABP, the major 
      pathogens were considered to be GNR as well as E. coli. On the other hand, in 
      CBP, GNR and E. faecalis, that were generally authorized to be pathogens, were 
      detected in less than half of the patients, and CNS were detected in the other 
      patients. Among the CNS cases, there were some cases that showed no relationship 
      between improvement of clinical symptoms and bacterial response. Therefore, it is 
      necessary to perform further studies on this matter. In conclusion, regarding the 
      criteria for clinical evaluation on bacterial prostatitis proposed by the 
      Japanese UTI committee, the treatment period for evaluation of efficacy was 
      appropriate, and it is necessary to perform further studies in order to determine 
      the pathogens in bacterial prostatitis.
FAU - Arakawa, S
AU  - Arakawa S
AD  - Department of Urology, Kobe University School of Medicine.
FAU - Kamidono, S
AU  - Kamidono S
FAU - Hirose, T
AU  - Hirose T
FAU - Kumamoto, Y
AU  - Kumamoto Y
FAU - Suzuki, K
AU  - Suzuki K
FAU - Ito, Y
AU  - Ito Y
FAU - Ban, Y
AU  - Ban Y
FAU - Kawada, Y
AU  - Kawada Y
FAU - Kumon, H
AU  - Kumon H
FAU - Ohmori, H
AU  - Ohmori H
AU  - et al.
LA  - jpn
PT  - Clinical Trial
PT  - English Abstract
PT  - Journal Article
PT  - Multicenter Study
PL  - Japan
TA  - Hinyokika Kiyo
JT  - Hinyokika kiyo. Acta urologica Japonica
JID - 0421145
RN  - 0 (Anti-Infective Agents)
RN  - 0 (Fluoroquinolones)
RN  - 0 (Quinolones)
RN  - 1WZ12GTT67 (temafloxacin)
SB  - IM
MH  - Acute Disease
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - *Anti-Infective Agents
MH  - Bacterial Infections/*drug therapy
MH  - Chronic Disease
MH  - *Fluoroquinolones
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Prostatitis/*drug therapy/microbiology
MH  - Quinolones/adverse effects/*therapeutic use
EDAT- 1994/05/01 00:00
MHDA- 1994/05/01 00:01
CRDT- 1994/05/01 00:00
PHST- 1994/05/01 00:00 [pubmed]
PHST- 1994/05/01 00:01 [medline]
PHST- 1994/05/01 00:00 [entrez]
PST - ppublish
SO  - Hinyokika Kiyo. 1994 May;40(5):455-66.